Scarica l'app Stockscreener
114.05
0.24%
-0.27
Pre-mercato:
117.49
3.44
+3.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BPMC Giù?
Forum
Previsione
Blueprint Medicines Corp Borsa (BPMC) Ultime notizie
Blueprint Medicines Co. (NASDAQ:BPMC) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Blueprint Medicines COO Christina Rossi sells shares worth $250,454 - MSN
Analysts’ Weekly Ratings Updates for Blueprint Medicines (BPMC) - Defense World
Blueprint Medicines (NASDAQ:BPMC) Given New $119.00 Price Target at Piper Sandler - Defense World
Analyst Expectations For Blueprint Medicines's Future - Benzinga
Blueprint Medicines stock target raised to $119 by Piper Sandler - Investing.com South Africa
Blueprint Medicines director Jeffrey Albers sells shares for $1.66 million - MSN
Blueprint Medicines CEO sells shares worth $159,407 - MSN
Blueprint Medicines Co. (NASDAQ:BPMC) Director Sells $1,660,584.33 in Stock - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells $250,458.36 in Stock - MarketBeat
Blueprint Medicines director Jeffrey Albers sells shares for $1.66 million By Investing.com - Investing.com South Africa
Blueprint Medicines COO Christina Rossi sells shares worth $250,454 By Investing.com - Investing.com South Africa
Insider Sell: Kate Haviland Sells Shares of Blueprint Medicines Corp (BPMC) - GuruFocus.com
Insider Sell: Christina Rossi Sells Shares of Blueprint Medicines Corp (BPMC) - GuruFocus.com
Blueprint Medicines CEO sells shares worth $159,407 By Investing.com - Investing.com Australia
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Empirical Asset Management LLC Acquires Shares of 26,921 Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
JMP Securities Reaffirms Market Outperform Rating for Blueprint Medicines (NASDAQ:BPMC) - Defense World
FY2027 Earnings Estimate for BPMC Issued By Leerink Partnrs - Defense World
FY2027 Earnings Forecast for BPMC Issued By Leerink Partnrs - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) vs. CV Sciences (OTCMKTS:CVSI) Financial Contrast - Defense World
Blueprint Medicines director Jeffrey Albers sells $511,400 in stock By Investing.com - Investing.com Canada
Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Director Sells 5,000 Shares of Stock - MarketBeat
Ariel Hurley Sells 2,250 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock - MarketBeat
Blueprint Medicines officer Hurley Ariel sells $225,000 in stock By Investing.com - Investing.com South Africa
Blueprint Medicines director Jeffrey Albers sells $511,400 in stock - Investing.com
Blueprint Medicines' SWOT analysis: stock surges on Ayvakit success - Investing.com
Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy - MSN
Blueprint Medicines (NASDAQ:BPMC) Shares Gap UpTime to Buy? - MarketBeat
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines - Yahoo Finance
Blueprint Medicines Corporation Updates Corporate Presentation at J.P. Morgan Healthcare Conference - Defense World
Blueprint Medicines (BPMC) Stock Jumps 18.2%: Will It Continue to Soar? - Yahoo Finance
Blueprint Medicines’ (BPMC) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Blueprint Medicines (NASDAQ:BPMC) Receives “Outperform” Rating from Wedbush - Defense World
Blueprint Medicines shares surge on growth strategy and upbeat trial data - Investing.com
Blueprint Medicines Highlights 2024 Achievements and Future Growth - TipRanks
Blueprint Medicines Surges Over 10% as 2025 Growth Strategy Ignites Investor - Yahoo Finance
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday - Benzinga
Blueprint Medicines' (BPMC) Outperform Rating Reiterated at Wedbush - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth - PR Newswire
Diversified Trust Co Sells 8,258 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
NUT Midline Carcinoma Treatment Market Research Report 2023-2024 & 2034: Market Forecast by Treatment, Route of Administration, and End-User Across 5 Regions and 17+ Countries - GlobeNewswire Inc.
Blueprint Medicines (NASDAQ:BPMC) Stock Price Up 5.7%Still a Buy? - MarketBeat
Stifel maintains Buy rating and $155 target on Blueprint Medicines stock - Investing.com
5.49%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):